Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker presented as an oral tablet for oral use. It is employed to prevent cerebral vasospasm following subarachnoid hemorrhage and to manage other cerebrovascular disorders in adult patients. It is marketed in the European Union and is available only by prescription, reflecting its specialized therapeutic role.

GNH USA supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on reliable quality and regulatory compliance.

Nimotop (nimodipine) is indicated for conditions affecting cerebral blood vessels where vasospasm risk is high.

- Subarachnoid hemorrhage: prevents delayed cerebral ischemia by reducing cerebral artery spasm. - Cerebral vasospasm: relaxes constricted cerebral arteries to improve blood flow. - Cerebrovascular disorders: supports cerebral perfusion in patients with compromised vascular tone.

Nimotop may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient drop in blood pressure. - Nausea: occasional gastrointestinal upset. - Flushing: warmth and redness of skin. - Dizziness: sensation of light‑headedness. - Peripheral edema: swelling of lower limbs.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure reduction requiring medical attention. - Bradycardia: abnormally slow heart rate. - Allergic reaction: rash, itching, or swelling. - Hepatotoxicity: elevated liver enzymes. - Neutropenia: reduced white blood cell count. - Stevens‑Johnson syndrome: severe skin eruption.

When prescribing Nimotop, clinicians should observe several safety considerations.

- Monitor blood pressure: watch for symptomatic hypotension. - Assess hepatic function: adjust use in patients with liver impairment. - Use caution in elderly: increased sensitivity to vasodilatory effects. - Avoid abrupt discontinuation: may precipitate rebound vasospasm. - Review concomitant vasodilators: risk of additive hypotension. - Store at room temperature: keep in original packaging, protect from moisture and light.

Nimotop can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase nimodipine plasma levels. - Other calcium channel blockers: additive vasodilatory effect leading to severe hypotension. - Grapefruit juice: may raise drug exposure and risk of adverse events.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: monitor blood pressure for excessive lowering. - Diuretics: watch for electrolyte disturbances and volume depletion. - Beta‑blockers: observe heart rate and blood pressure. - Anticonvulsants (e.g., carbamazepine): may reduce nimodipine concentrations. - NSAIDs: potential impact on renal function when combined with vasodilators.